Furthermore, detailed knowledge of natural HLA class II antigen presentation patterns will allow for tailoring multi-epitope peptide vaccines containing both HLA class I- and HLA class II-restricted targets, which may induce and boost synergistic CD8+ and CD4+ anti-tumor responses. This evidence concerns the gene CD4 and neoplasm.